I'm sorry BB, but I just don't believe it. I do think mRNA has been great for the likes of Covid-19, but I believe that practically every individual cancer has idiosyncrasies of it's own. We get at these by using the person and their cancer as part of the solution. I don't believe the same can possibly be said of mRNA.
I'm not suggesting that the technology won't create better products than are currently available, they may be the answer to cures, especially when combined with the DCVax's.
I really don't know why we refer to cancer like it was a single disease. I have no idea how many ways you can break it down to. It seems like the deeper you go into a specific type of cancer the more you realize just how many variations it has. I believe we have the tools to work on all of them with a personalized vaccine, I don't believe you can say the same with mRNA based products.
I won't be around in 50 years, but I'd be willing to bet that by then many different diseases will be cured with personalized products, most which come from the blood alone. I would suspect that many such products will be made in a matter of hours, instead of days, and when ill you'll make an appointment for the initial blood processing, then probably come back the next day and receive the treatment. The blood product that's provided will not only result in part of the solution, it will also say what therapeutics need to be added to achieve a cure. Of course this assumes that we'll still have an inhabitable planet in 50 years, that too may be in doubt.
As for NWBO, if BP is unwilling to participate as either a buyer or a partner at a price NWBO will accepts, I feel reasonably confident that NWBO, especially after the FlaskWork device is approved, could go it alone, at least for quite awhile. I believe that by the time they're using the FlaskWork device to provide DCVax's all over the world BP will be pouting over their mistakes, and I really don't know that any offer can be high enough to consider accepting. Imagine the value of the company if most solid cancers benefit from its use.
I'm not putting down other technologies, I believe they all contribute. I do have stock in PSTI which uses placental cells, it turns out that they have no DNA identification, so anyone can utilize them without fear of rejection. I believe over time they may be found effective for many things, but they have a ways to go. I believe the key is the placental stem cells can sense what needs to be done, and adapt to doing it. I believe we're a long way from understanding how they do it, but what's important is the company can make 20,000 doses of their products from a single placenta.
The only real question here is, will the DCVax's play a roll in conquering cancer. I believe that Dr. Liau is confident that at least for GBM they'll be a part of the solution that will cure a lot of people. I believe that she knows what she's talking about. As for other cancers, time will tell. If NWBO is a key in dealing with GBM, I've got to believe that $20 or more is reasonable, if on the other hand it works in numerous solid cancers, just move the decimal point as it grows if it's not bought out.
Gary
Market Data 
Markets 
